Article PDF
Avoid common mistakes on your manuscript.
References
Bai, C., Zhong, Q., and Gao, G.F. (2022). Overview of SARS-CoV-2 genome-encoded proteins. Sci China Life Sci 65, 280–294.
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T.S., Herrler, G., Wu, N.H., Nitsche, A., et al. (2020). SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 181, 271–280.e8.
Hsieh, P.K., Chang, S.C., Huang, C.C., Lee, T.T., Hsiao, C.W., Kou, Y.H., Chen, I.Y., Chang, C.K., Huang, T.H., and Chang, M.F. (2005). Assembly of severe acute respiratory syndrome coronavirus RNA packaging signal into virus-like particles is nucleocapsid dependent. J Virol 79, 13848–13855.
Hu, B., Guo, H., Zhou, P., and Shi, Z.L. (2021). Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol 19, 141–154.
Jiang, S., Tang, Y., Xiang, L., Zhu, X., Cai, Z., Li, L., Chen, Y., Chen, P., Feng, Y., Lin, X., et al. (2021). Efficient de novo assembly and modification of large DNA fragments. Sci China Life Sci, doi: https://doi.org/10.1007/s11427-021-2029-0.
Kim, D., Lee, J.Y., Yang, J.S., Kim, J.W., Kim, V.N., and Chang, H. (2020). The architecture of SARS-CoV-2 transcriptome. Cell 181, 914–921.e10.
Li, Q., Wu, J., Nie, J., Zhang, L., Hao, H., Liu, S., Zhao, C., Zhang, Q., Liu, H., Nie, L., et al. (2020). The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity. Cell 182, 1284–1294.e9.
Ma, Y., Mao, G., Wu, G., Chen, M., Qin, F., Zheng, L., and Zhang, X.E. (2021). Dual-fluorescence labeling pseudovirus for real-time imaging of single SARS-CoV-2 entry in respiratory epithelial cells. ACS Appl Mater Interfaces 13, 24477–24486.
Pancer, K., Milewska, A., Owczarek, K., Dabrowska, A., Kowalski, M., Łabaj, P.P., Branicki, W., Sanak, M., and Pyrc, K. (2020). The SARS-CoV-2 ORF10 is not essential in vitro or in vivo in humans. PLoS Pathog 16, e1008959.
Acknowledgements
We are grateful to Dr. Xiaoping Xiao at Shenzhen Center for Disease Control and Prevention for help on the biosafety test in BSL-3 laboratory. This work was supported by Strategic Priority Research Program of the Chinese Academy of Sciences, China (XDB29050100), National Natural Science Foundation (21890743, 31725002), Youth Innovation Promotion Association CAS (2021359), Natural Science Foundation of Guangdong (2018B030306046, 2020A1515111130), Shenzhen Science and Technology Program (KQTD20180413181837372), Guangdong Provincial Key Laboratory of Synthetic Genomics (2019B030301006) and Shenzhen Outstanding Talents Training Fund.
Author information
Authors and Affiliations
Corresponding authors
Additional information
Compliance and ethics
The author(s) declare that they have no conflict of interest. J.D., Y.M., and G.M. have filed a patent on the split-viral-genome system of SARS-CoV-2. The SARS-CoV-2 genomes used in this study are according with Genebank #MN908947-3. The materials and used in this study are listed in Supplementary Materials.
Rights and permissions
About this article
Cite this article
Ma, Y., Mao, G., Yang, W. et al. Studying bona fide SARS-CoV-2 biology in a BSL-2 biosafety environment using a split-virus-genome system. Sci. China Life Sci. 65, 1894–1897 (2022). https://doi.org/10.1007/s11427-022-2114-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11427-022-2114-8